{"disease":{"id":"bacterial-infection","name":"bacterial infection"},"drugs":{"marketed":[{"drug_id":"cefiderocol","indication_name":"Gram-Negative Bacterial Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetroja","generic_name":"CEFIDEROCOL","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":"300","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death."},{"drug_id":"cefiderocol","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetroja","generic_name":"CEFIDEROCOL","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":"300","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death."},{"drug_id":"dalbavancin","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dalvance","generic_name":"DALBAVANCIN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Lipoglycopeptide Antibacterial","quality_score":65,"revenue":"260.0","mechanism":"Dalvance works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death."},{"drug_id":"mezlocillin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"bacitracin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"BACITRACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"bacitracin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxycyclin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"gentamicin","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"cycloserine","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefradine","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefradex","generic_name":"cefradine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefradine","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"cefapirin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefaprin","generic_name":"cefapirin","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"cefapirin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"cefazolin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFAZOLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefazolin-sodium","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"Cefazolin Sodium","company_name":"GSK","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":60,"revenue":null,"mechanism":"Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"omadacycline-tosylate","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE TOSYLATE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"tobramycin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"tobramycin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"tobramycin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefepime","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"cefepime","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"oritavancin","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orbactiv","generic_name":"ORITAVANCIN","company_name":"Melinta Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Lipoglycopeptide Antibacterial","quality_score":65,"revenue":null,"mechanism":"Orbactiv works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death."},{"drug_id":"sulfamethoxazole","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantanol","generic_name":"SULFAMETHOXAZOLE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"moxifloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"omadacycline","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"trimethoprim","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chloramphenicol","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlorocidin","generic_name":"CHLORAMPHENICOL","company_name":"Parkedale","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Amphenicol-class Antibacterial","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime-axetil","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"sulfadiazine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftaroline","indication_name":"Acute bacterial skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftaroline Fosamil","generic_name":"CEFTAROLINE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins."},{"drug_id":"cefepime-hydrochloride","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"cefepime-hydrochloride","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"carindacillin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardinacillin","generic_name":"carindacillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"sulfamethizole","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfurine","generic_name":"SULFAMETHIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sulfamethizole","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"betaine","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cystadane","generic_name":"BETAINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Methylating Agent [EPC]","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"piperacillin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"amoxicillin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"xydalba","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xydalba","company_name":"Correvio International Sarl","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cefepim","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cefepim","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"chlortetracycline","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aureomycin","generic_name":"CHLORTETRACYCLINE","company_name":"","drug_phase":"marketed","molecular_target":"Protein-arginine deiminase type-4","drug_class":"chlortetracycline","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"cefamandole","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefamandole","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"nalidixic-acid","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nalidixate","generic_name":"NALIDIXIC ACID","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"nalidixic acid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"retapamulin","indication_name":"Superficial bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altabax","generic_name":"RETAPAMULIN","company_name":"Almirall","drug_phase":"marketed","molecular_target":"","drug_class":"Pleuromutilin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alatrofloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"avelox","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lignocaine","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"orbactiv","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Orbactiv","company_name":"Melinta Therapeutics, LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"neomycin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"lidocaine-hydrochloride","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"sulfacytine","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renoquid","generic_name":"SULFACYTINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sulfacytine","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"benzethonium","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzetonium Chloride","generic_name":"BENZETHONIUM","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"benzethonium","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxon","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avibactam","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avycaz","generic_name":"AVIBACTAM","company_name":"Cerexa Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor [EPC]","quality_score":54,"revenue":null,"mechanism":"EMBLAVEO is an antibacterial drug."},{"drug_id":"gatifloxacin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"aztreonam","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"aztreonam","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"aztreonam","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"methenamine","indication_name":"Prevention of Bacterial Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hiprex","generic_name":"METHENAMINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"methenamine","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"dyclonine","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dyclone","generic_name":"DYCLONINE","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"dyclonine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"polymyxin-b","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"imipenem","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"imipenem","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"amikacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ceftazidime","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefoxitin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefonicid","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monocid","generic_name":"CEFONICID","company_name":"","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefonicid","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"faropenem-medoxil","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Faropenem Daloxate","generic_name":"faropenem medoxil","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Faropenem Daloxate works by inhibiting bacterial cell wall synthesis."},{"drug_id":"faropenem","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fropenem","generic_name":"FAROPENEM","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"faropenem","quality_score":null,"revenue":null,"mechanism":"Faropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefpodoxime-proxetil","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftaroline-fosamil","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Teflaro","generic_name":"CEFTAROLINE FOSAMIL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":70,"revenue":null,"mechanism":"Teflaro works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefotetan","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefotan","generic_name":"CEFOTETAN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cefotetan","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefotan","generic_name":"CEFOTETAN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cilastatin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"cilastatin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"azlocillin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZLOCILLIN","company_name":"Bayer Pharmaceuticals Corp","drug_phase":"marketed","molecular_target":"","drug_class":"azlocillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"azlocillin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZLOCILLIN","company_name":"Bayer Pharmaceuticals Corp","drug_phase":"marketed","molecular_target":"","drug_class":"azlocillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefalotin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cephalotin","generic_name":"cefalotin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 8","drug_class":"cefalotin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"cefalexin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keflex","generic_name":"cefalexin","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Solute carrier family 15 member 2","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"benzalkonium","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzododecinium","generic_name":"BENZALKONIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"benzalkonium","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"benzocaine","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norcaine","generic_name":"BENZOCAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"sparfloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sparcin","generic_name":"SPARFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"clavulanic-acid","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"clavulanic-acid","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"tazicef","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"tazicef","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"silvadene","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silvadene","generic_name":"Silver Sulfadiazine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"bacterial cell membrane and cell wall","drug_class":"sulfonamide antimicrobial","quality_score":10,"revenue":null,"mechanism":"Silver sulfadiazine acts on bacterial cell membrane and cell wall to produce bactericidal effect."},{"drug_id":"norfloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"carbenicillin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carboxybenzylpenicillin","generic_name":"CARBENICILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"delafloxacin","indication_name":"Bacterial infection of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baxdela","generic_name":"DELAFLOXACIN","company_name":"Melinta","drug_phase":"marketed","molecular_target":"","drug_class":"Fluoroquinolone Antibacterial","quality_score":65,"revenue":null,"mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA."},{"drug_id":"ciprofloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"cephradin","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephradin","company_name":"Sohag University","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cephazolin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephazolin","company_name":"HaEmek Medical Center, Israel","drug_phase":"phase_1","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cefazoline","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefazoline","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cystadane","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cystadane","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Bacterial infection due to Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seromycin","indication_name":"Bacterial urinary infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"seromycin","company_name":"Massachusetts General Hospital","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4, Glutamate receptor ionotropic, NMDA 1, Glutamate receptor ionotropic, NMDA 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"omadacycline-tosylate","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE TOSYLATE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"xylocain","indication_name":"Prevent Minor Bacterial Skin Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"delafloxacin","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baxdela","generic_name":"DELAFLOXACIN","company_name":"Melinta","drug_phase":"marketed","molecular_target":"","drug_class":"Fluoroquinolone Antibacterial","quality_score":65,"revenue":null,"mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA."},{"drug_id":"mezlocillin","indication_name":"Bacterial infection due to Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":165,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05353634","title":"Metagenomic Sequencing in Clinical Infectious Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2022097,"lead_sponsor_name":"Liaocheng People's Hospital","has_results":false},{"nct_id":"NCT04256395","title":"Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":102456,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT05561504","title":"Helicobacter Pylori Local Prevalence and Antibiotic Resistance","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT06377592","title":"Development and Accuracy Evaluation of Gram Staining Analysis AI","phase":"","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"GramEye","has_results":false},{"nct_id":"NCT06764576","title":"Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis","phase":"","overall_status":"RECRUITING","enrollment_count":13000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06620341","title":"A Cluster Randomized Controlled Trial to Compare the Rate of Antibiotic Infusion","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":11900,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03499652","title":"Neonatal Bacterial Meningitis Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04633603","title":"LázBarát™ (FeverFriend™) Projekt: Attitude Toward Fever and Its Change in the Healthcare System","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of Pecs","has_results":false},{"nct_id":"NCT04228081","title":"MicroUDxTM: a Rapid Diagnostic Tool That Will Prevent Death and Disability From Common Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT03397433","title":"ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record","phase":"NA","overall_status":"COMPLETED","enrollment_count":9673,"lead_sponsor_name":"Endeavor Health","has_results":false},{"nct_id":"NCT03646227","title":"Multi-Drug Resistant Organism Network","phase":"","overall_status":"COMPLETED","enrollment_count":6496,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT07226557","title":"Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT04841369","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3420,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT06178822","title":"Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room","phase":"","overall_status":"RECRUITING","enrollment_count":3300,"lead_sponsor_name":"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)","has_results":false},{"nct_id":"NCT06472765","title":"Vaginal Ecosystem and Network in the United States Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3250,"lead_sponsor_name":"Vaginal Biome Science","has_results":false},{"nct_id":"NCT04036318","title":"Evaluation of Presumptive Periodic Treatment (PPT) of Sexually Transmitted Infections (STIs)","phase":"","overall_status":"COMPLETED","enrollment_count":3022,"lead_sponsor_name":"National Institute for Medical Research, Tanzania","has_results":false},{"nct_id":"NCT06260345","title":"CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Association Clinique Thérapeutique Infantile du val de Marne","has_results":false},{"nct_id":"NCT01340937","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2808,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05686577","title":"How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care","phase":"","overall_status":"COMPLETED","enrollment_count":2411,"lead_sponsor_name":"University Hospital, Tours","has_results":false},{"nct_id":"NCT03767374","title":"Risk-factors for Multidrug-resistant Bacteria Colonization Among Patients at High Risk of STIs","phase":"","overall_status":"COMPLETED","enrollment_count":2186,"lead_sponsor_name":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","has_results":false},{"nct_id":"NCT03925480","title":"Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2110,"lead_sponsor_name":"Murdoch Childrens Research Institute","has_results":false},{"nct_id":"NCT05259683","title":"Febrile Infant Diagnostic Assessment and Outcome Study","phase":"","overall_status":"COMPLETED","enrollment_count":2076,"lead_sponsor_name":"Queen's University, Belfast","has_results":false},{"nct_id":"NCT05336851","title":"Emergency PWAS in Respiratory Infectious Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07110636","title":"Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Karius, Inc.","has_results":false},{"nct_id":"NCT06419426","title":"Prospective Study on Febrile Batteries in Pediatric Oncohaematological Patients (SuBiTo)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Associazione Italiana Ematologia Oncologia Pediatrica","has_results":false},{"nct_id":"NCT06769815","title":"Host Immunity, Plasmodium and Pathogens Co-Infections","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institut Pasteur","has_results":false},{"nct_id":"NCT07134751","title":"Febrile Infants Swedish Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT06018792","title":"Molecular Culture for the Diagnosis of Pediatric Sepsis","phase":"","overall_status":"RECRUITING","enrollment_count":1835,"lead_sponsor_name":"Jip Groen","has_results":false},{"nct_id":"NCT05641025","title":"Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis","phase":"","overall_status":"COMPLETED","enrollment_count":1774,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT05722184","title":"Diagnostic Evaluation Study of the BactInsight Blood Culture System in West-Africa","phase":"","overall_status":"COMPLETED","enrollment_count":1724,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT06391463","title":"Multi-resistant and Spore-forming Bacteria in a Neonatal Intensive Care Unit","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT01337167","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1473,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07111793","title":"Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics","phase":"NA","overall_status":"RECRUITING","enrollment_count":1401,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT01480258","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1315,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT03752476","title":"Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria","phase":"","overall_status":"UNKNOWN","enrollment_count":1300,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT01341639","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"MCM Vaccines B.V.","has_results":true},{"nct_id":"NCT03671967","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1084,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT07261969","title":"CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan","phase":"NA","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06634940","title":"International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT03163628","title":"biomArkers to differeNtiate bacTerial From vIral iNfEctions","phase":"NA","overall_status":"COMPLETED","enrollment_count":983,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03475472","title":"Direct Molecular Characterization of Bacteria From ICU and From the REHAB","phase":"","overall_status":"COMPLETED","enrollment_count":971,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT04688216","title":"Developing a Risk Assessment System of Multidrug-resistant Organisms Infection","phase":"","overall_status":"COMPLETED","enrollment_count":917,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03941951","title":"Study to Optimize the Use of New Antibiotics","phase":"NA","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT03761043","title":"Nurse Promotion of IV to PO Antimicrobial Conversion","phase":"NA","overall_status":"COMPLETED","enrollment_count":853,"lead_sponsor_name":"Kelowna General Hospital","has_results":false},{"nct_id":"NCT05146570","title":"Early Diagnosis of Native and Device-associated Meningitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":842,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT03996967","title":"Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia","phase":"","overall_status":"COMPLETED","enrollment_count":837,"lead_sponsor_name":"Boston University","has_results":false},{"nct_id":"NCT02852902","title":"Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.","phase":"","overall_status":"COMPLETED","enrollment_count":820,"lead_sponsor_name":"Spanish Network for Research in Infectious Diseases","has_results":false},{"nct_id":"NCT05942157","title":"Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections","phase":"NA","overall_status":"UNKNOWN","enrollment_count":810,"lead_sponsor_name":"Singapore General Hospital","has_results":false},{"nct_id":"NCT03192072","title":"A Rapid Test for Acute Respiratory Illness","phase":"","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"Duke University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}